Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

83 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression.
Thase ME, Rush AJ, Howland RH, Kornstein SG, Kocsis JH, Gelenberg AJ, Schatzberg AF, Koran LM, Keller MB, Russell JM, Hirschfeld RM, LaVange LM, Klein DN, Fawcett J, Harrison W. Thase ME, et al. Among authors: lavange lm. Arch Gen Psychiatry. 2002 Mar;59(3):233-9. doi: 10.1001/archpsyc.59.3.233. Arch Gen Psychiatry. 2002. PMID: 11879161 Clinical Trial.
Sertraline versus imipramine to prevent relapse in chronic depression.
Koran LM, Gelenberg AJ, Kornstein SG, Howland RH, Friedman RA, DeBattista C, Klein D, Kocsis JH, Schatzberg AF, Thase ME, Rush AJ, Hirschfeld RM, LaVange LM, Keller MB. Koran LM, et al. Among authors: lavange lm. J Affect Disord. 2001 Jun;65(1):27-36. doi: 10.1016/s0165-0327(00)00272-x. J Affect Disord. 2001. PMID: 11426506 Clinical Trial.
A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP).
Stroup TS, McEvoy JP, Ring KD, Hamer RH, LaVange LM, Swartz MS, Rosenheck RA, Perkins DO, Nussbaum AM, Lieberman JA; Schizophrenia Trials Network. Stroup TS, et al. Among authors: lavange lm. Am J Psychiatry. 2011 Sep;168(9):947-56. doi: 10.1176/appi.ajp.2011.10111609. Epub 2011 Jul 18. Am J Psychiatry. 2011. PMID: 21768610 Free PMC article. Clinical Trial.
Phase 2 randomized safety and efficacy trial of nebulized denufosol tetrasodium in cystic fibrosis.
Deterding RR, Lavange LM, Engels JM, Mathews DW, Coquillette SJ, Brody AS, Millard SP, Ramsey BW; Cystic Fibrosis Therapeutics Development Network and the Inspire 08-103 Working Group. Deterding RR, et al. Among authors: lavange lm. Am J Respir Crit Care Med. 2007 Aug 15;176(4):362-9. doi: 10.1164/rccm.200608-1238OC. Epub 2007 Apr 19. Am J Respir Crit Care Med. 2007. PMID: 17446337 Clinical Trial.
Safety and tolerability of denufosol tetrasodium inhalation solution, a novel P2Y2 receptor agonist: results of a phase 1/phase 2 multicenter study in mild to moderate cystic fibrosis.
Deterding R, Retsch-Bogart G, Milgram L, Gibson R, Daines C, Zeitlin PL, Milla C, Marshall B, Lavange L, Engels J, Mathews D, Gorden J, Schaberg A, Williams J, Ramsey B; Cystic Fibrosis Foundation Therapeutics Development Network. Deterding R, et al. Pediatr Pulmonol. 2005 Apr;39(4):339-48. doi: 10.1002/ppul.20192. Pediatr Pulmonol. 2005. PMID: 15704203 Clinical Trial.
83 results